A comparative study of the efficiency of HCV NS3/4A protease drugs against different HCV genotypes using in silico approaches
Authors:
- 1 January 2019
- journal article
- research article
- Published by Elsevier in Life Sciences
- Vol. 217, 176-184
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- GalaxyRefine: protein structure refinement driven by side-chain repackingNucleic Acids Research, 2013
- Open Babel: An open chemical toolboxJournal of Cheminformatics, 2011
- Molecular Mechanisms of Viral and Host Cell Substrate Recognition by Hepatitis C Virus NS3/4A ProteaseJournal of Virology, 2011
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor bindingProceedings of the National Academy of Sciences, 2010
- Hepatitis C Virus Non-structural Protein 3 (HCV NS3): A Multifunctional Antiviral TargetJournal of Biological Chemistry, 2010
- MK-7009, a Potent and Selective Inhibitor of Hepatitis C Virus NS3/4A ProteaseAntimicrobial Agents and Chemotherapy, 2010
- AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreadingJournal of Computational Chemistry, 2009
- MolProbity: all-atom contacts and structure validation for proteins and nucleic acidsNucleic Acids Research, 2007
- Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3Cell, 2005
- MUSCLE: multiple sequence alignment with high accuracy and high throughputNucleic Acids Research, 2004